CYLTEZO笔在生物制剂自动注射器患者和医疗专业人士中的接受度

数据集获取（Figshare）

• 源站标题：Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals
• DOI：10.6084/m9.figshare.26861539.v1
• 发布日期：2024-08-28
• 文件数：3 个
• 文件总体积：620.55 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Acceptability_of_CYLTEZO_pen_among_biologics_autoinjector_patients_autoinjector_Na_ve_patients_and_healthcare_professionals/26861539

命令行下载

curl -L -o "iedd_a_2394112_sm9416.docx" "https://ndownloader.figshare.com/files/48847099"
curl -L -o "iedd_a_2394112_sm9415.docx" "https://ndownloader.figshare.com/files/48847102"
curl -L -o "iedd_a_2394112_sm9414.docx" "https://ndownloader.figshare.com/files/48847105"

文件清单

• iedd_a_2394112_sm9416.docx（16.75 KB）
• iedd_a_2394112_sm9415.docx（490.80 KB）
• iedd_a_2394112_sm9414.docx（113.00 KB）

文件总体积 620.55 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Cyltezo® (Adalimumab-adbm) is an FDA-approved interchangeable biosimilar for Humira® (adalimumab reference product [RP]) that helps treat chronic inflammatory conditions. Adalimumab-adbm is administered via an autoinjector, the adalimumab-adbm pen. This study assessed user opinions related to usability, perceptions, convenience, safety features, and acceptability of the adalimumab-adbm pen.
98 Humira Pen users, 100 biologics pen naïve patients, and 99 health care professionals simulated use of the adalimumab-adbm pen on injection pads. Opinions were captured with a validated questionnaire using Likert-type scales during moderated interviews. Binomial tests were conducted for top-two ratings percentages.
Nearly 90% of participants found the adalimumab-adbm pen ‘easy’ or ‘very easy’ to use, handle, and learn how to use. Almost 90% of volunteers thought the pen was ‘very’ or ‘extremely’ solid and convenient to use at home. Around 80% found the pen to be ‘very’ or ‘extremely’ comfortable. Over 90% of respondents said they would be ‘satisfied’ or ‘very satisfied’ with the safety features and the device itself. Nearly 90% of respondents indicated being ‘very’ or ‘extremely’ open to adopting the adalimumab-adbm pen.
The adalimumab-adbm pen provided users with a positive experience with features that benefit perceptions of usability, handling, safety, convenience, and acceptability.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.26861539.v1（source: https://tandf.figshare.com/articles/dataset/Acceptability_of_CYLTEZO_pen_among_biologics_autoinjector_patients_autoinjector_Na_ve_patients_and_healthcare_professionals/26861539）。